Prokidney Corp. (PROK) fundamentals score
Prokidney is a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease (“CKD”) and diabetes.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 4.3 out of 10, Weak long-term fundamentals
- Growth: 5.8/10
- Profitability: 4.0/10
- Financial health: 5.2/10
- Earnings quality: 1.2/10
- Valuation: not scored
Scores are calculated from Prokidney Corp.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10